|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ascha MS, Hanouneh IA, Lopez R, Tamimi TA,
Feldstein AF and Zein NN: The incidence and risk factors of
hepatocellular carcinoma in patients with nonalcoholic
steatohepatitis. Hepatology. 51:1972–1978. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273.e1. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Torre LA, Siegel RL, Ward EM and Jemal A:
Global cancer incidence and mortality rates and trends-an update.
Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Naugler WE, Sakurai T, Kim S, Maeda S, Kim
K, Elsharkawy AM and Karin M: Gender disparity in liver cancer due
to sex differences in MyD88-dependent IL-6 production. Science.
317:121–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang SH, Yeh SH, Lin WH, Wang HY, Chen DS
and Chen PJ: Identification of androgen response elements in the
enhancer I of hepatitis B virus: A mechanism for sex disparity in
chronic hepatitis B. Hepatology. 50:1392–1402. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu C, Ren YF, Dong J, Ke MY, Ma F, Monga
SPS, Wu R, Lv Y and Zhang XF: Activation of SRY accounts for
male-specific hepatocarcinogenesis: Implication in gender disparity
of hepatocellular carcinoma. Cancer Lett. 410:20–31. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jiang HL, Xu D, Yu H, Ma X, Lin GF, Ma DY
and Jin JZ: DAX-1 inhibits hepatocellular carcinoma proliferation
by inhibiting β-catenin transcriptional activity. Cell Physiol
Biochem. 34:734–742. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chua HH, Tsuei DJ, Lee PH, Jeng YM, Lu J,
Wu JF, Su DS, Chen YH, Chien CS, Kao PC, et al: RBMY, a novel
inhibitor of glycogen synthase kinase 3β, increases tumor stemness
and predicts poor prognosis of hepatocellular carcinoma.
Hepatology. 62:1480–1496. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bertani S, Pineau P, Loli S, Moura J,
Zimic M, Deharo E and Ruiz E: An atypical age-specific pattern of
hepatocellular carcinoma in Peru: A threat for Andean populations.
PLoS One. 8:e677562013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hassan MM, Botrus G, Abdel-Wahab R, Wolff
RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, et al:
Estrogen replacement reduces risk and increases survival times of
women with hepatocellular carcinoma. Clin Gastroenterol Hepatol.
15:1791–1799. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu MW, Chang HC, Chang SC, Liaw YF, Lin
SM, Liu CJ, Lee SD, Lin CL, Chen PJ, Lin SC and Chen CJ: Role of
reproductive factors in hepatocellular carcinoma: Impact on
hepatitis B- and C-related risk. Hepatology. 38:1393–1400. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bigsby RM and Caperell-Grant A: The role
for estrogen receptor-alpha and prolactin receptor in sex-dependent
DEN-induced liver tumorigenesis. Carcinogenesis. 32:1162–1166.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Prieto J: Inflammation, HCC and sex: IL-6
in the centre of the triangle. J Hepatol. 48:380–381. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang YC, Xu GL, Jia WD, Han SJ, Ren WH,
Wang W, Liu WB, Zhang CH and Chen H: Estrogen suppresses metastasis
in rat hepatocellular carcinoma through decreasing interleukin-6
and hepatocyte growth factor expression. Inflammation. 35:143–149.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Karin M: Nuclear factor-kappaB in cancer
development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shi L, Feng Y, Lin H, Ma R and Cai X: Role
of estrogen in hepatocellular carcinoma: Is inflammation the key? J
Transl Med. 12:932014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ren J, Chen GG, Liu Y, Su X, Hu B, Leung
BC, Wang Y, Ho RL, Yang S, Lu G, et al: Cytochrome P450 1A2
metabolizes 17β-estradiol to suppress hepatocellular carcinoma.
PLoS One. 11:e01538632016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zheng B, Zhu YJ, Wang HY and Chen L:
Gender disparity in hepatocellular carcinoma (HCC): Multiple
underlying mechanisms. Sci China Life Sci. 60:575–584. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Teng Y, Litchfield LM, Ivanova MM, Prough
RA, Clark BJ and Klinge CM: Dehydroepiandrosterone-induces miR-21
transcription in HepG2 cells through estrogen receptor β and
androgen receptor. Mol Cell Endocrinol. 392:23–36. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shen M, Cao J and Shi H: Effects of
estrogen and estrogen receptors on transcriptomes of HepG2 Cells: A
preliminary study using RNA sequencing. Int J Endocrinol.
2018:57891272018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shen M and Shi H: Estradiol and estrogen
receptor agonists oppose oncogenic actions of leptin in HepG2
cells. PLoS One. 11:e01514552016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pearce ST and Jordan VC: The biological
role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol
Hematol. 50:3–22. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Iyer JK, Kalra M, Kaul A, Payton ME and
Kaul R: Estrogen receptor expression in chronic hepatitis C and
hepatocellular carcinoma pathogenesis. World J Gastroenterol.
23:6802–6816. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu H, Wei Y, Zhang Y, Xu Y, Li F, Liu J,
Zhang W, Han X, Tan R and Shen P: Oestrogen attenuates tumour
progression in hepatocellular carcinoma. J Pathol. 228:216–229.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wei Q, Guo P, Mu K, Zhang Y, Zhao W, Huai
W, Qiu Y, Li T, Ma X, Liu Y, et al: Estrogen suppresses
hepatocellular carcinoma cells through ERβ-mediated upregulation of
the NLRP3 inflammasome. Lab Invest. 95:804–816. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hou J, Xu J, Jiang R, Wang Y, Chen C, Deng
L, Huang X, Wang X and Sun B: Estrogen-sensitive PTPRO expression
represses hepatocellular carcinoma progression by control of STAT3.
Hepatology. 57:678–688. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang W, Lu Y, Xu Y, Xu L, Zheng W, Wu Y,
Li L and Shen P: Estrogen represses hepatocellular carcinoma (HCC)
growth via inhibiting alternative activation of tumor-associated
macrophages (TAMs). J Biol Chem. 287:40140–40149. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Deng L, Yang H, Tang J, Lin Z, Yin A, Gao
Y, Wang X, Jiang R and Sun B: Inhibition of MTA1 by ERα contributes
to protection hepatocellular carcinoma from tumor proliferation and
metastasis. J Exp Clin Cancer Res. 34:1282015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lin YM, Velmurugan BK, Yeh YL, Tu CC, Ho
TJ, Lai TY, Tsai CH, Tsai FJ, Tsai CH and Huang CY: Activation of
estrogen receptors with E2 downregulates peroxisome
proliferator-activated receptor γ in hepatocellular carcinoma.
Oncol Rep. 30:3027–3031. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bartel DP and Chen CZ: Micromanagers of
gene expression: The potentially widespread influence of metazoan
microRNAs. Nat Rev Genet. 5:396–400. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Amodio G, Sasso E, D'Ambrosio C, Scaloni
A, Moltedo O, Franceschelli S, Zambrano N and Remondelli P:
Identification of a microRNA (miR-663a) induced by ER stress and
its target gene PLOD3 by a combined microRNome and proteome
approach. Cell Biol Toxicol. 32:285–303. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sun L, Guo Z, Sun J, Li J, Dong Z, Zhang
Y, Chen J, Kan Q and Yu Z: MiR-133a acts as an anti-oncogene in
Hepatocellular carcinoma by inhibiting FOSL2 through TGF-β/Smad3
signaling pathway. Biomed Pharmacother. 107:168–176. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ladeiro Y, Couchy G, Balabaud C,
Bioulac-Sage P, Pelletier L, Rebouissou S and Zucman-Rossi J:
MicroRNA profiling in hepatocellular tumors is associated with
clinical features and oncogene/tumor suppressor gene mutations.
Hepatology. 47:1955–1963. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen PJ, Yeh SH, Liu WH, Lin CC, Huang HC,
Chen CL, Chen DS and Chen PJ: Androgen pathway stimulates
microRNA-216a transcription to suppress the tumor suppressor in
lung cancer-1 gene in early hepatocarcinogenesis. Hepatology.
56:632–643. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sun J, Lu H, Wang X and Jin H: MicroRNAs
in hepatocellular carcinoma: Regulation, function, and clinical
implications. ScientificWorldJournal. 2013:9242062013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Marchesi F, Regazzo G, Palombi F,
Terrenato I, Sacconi A, Spagnuolo M, Donzelli S, Marino M, Ercolani
C, Di Benedetto A, et al: Serum miR-22 as potential non-invasive
predictor of poor clinical outcome in newly diagnosed, uniformly
treated patients with diffuse large B-cell lymphoma: An explorative
pilot study. J Exp Clin Cancer Res. 37:952018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jiang R, Deng L, Zhao L, Li X, Zhang F,
Xia Y, Gao Y, Wang X and Sun B: miR-22 promotes HBV-related
hepatocellular carcinoma development in males. Clin Cancer Res.
17:5593–5603. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu WH, Yeh SH, Lu CC, Yu SL, Chen HY, Lin
CY, Chen DS and Chen PJ: MicroRNA-18a prevents estrogen
receptor-alpha expression, promoting proliferation of
hepatocellular carcinoma cells. Gastroenterology. 136:683–693.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li CL, Yeh KH, Liu WH, Chen CL, Chen DS,
Chen PJ and Yeh SH: Elevated p53 promotes the processing of miR-18a
to decrease estrogen receptor-α in female hepatocellular carcinoma.
Int J Cancer. 136:761–770. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Luu-The V: Assessment of steroidogenesis
and steroidogenic enzyme functions. J Steroid Biochem Mol Biol.
137:176–182. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Niu ZS, Niu XJ and Wang WH: Genetic
alterations in hepatocellular carcinoma: An update. World J
Gastroenterol. 22:9069–9095. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Aleksic K, Lackner C, Geigl JB, Schwarz M,
Auer M, Ulz P, Fischer M, Trajanoski Z, Otte M and Speicher MR:
Evolution of genomic instability in diethylnitrosamine-induced
hepatocarcinogenesis in mice. Hepatology. 53:895–904. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Na TY, Ka NL, Rhee H, Kyeong D, Kim MH,
Seong JK, Park YN and Lee MO: Interaction of hepatitis B virus X
protein with PARP1 results in inhibition of DNA repair in
hepatocellular carcinoma. Oncogene. 35:5435–5445. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhao Z, Chen GY, Long J, Li H and Huang J:
Genomic losses at 5q13.2 and 8p23.1 in dysplastic hepatocytes are
common events in hepatitis B virus-related hepatocellular
carcinoma. Oncol Lett. 9:2839–2846. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tummala KS, Gomes AL, Yilmaz M, Graña O,
Bakiri L, Ruppen I, Ximénez-Embún P, Sheshappanavar V,
Rodriguez-Justo M, Pisano DG, et al: Inhibition of de novo NAD(+)
synthesis by oncogenic URI causes liver tumorigenesis through DNA
damage. Cancer Cell. 26:826–839. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Mazzotta A, Partipilo G, De Summa S,
Giotta F, Simone G and Mangia A: Nuclear PARP1 expression and its
prognostic significance in breast cancer patients. Tumour Biol.
37:6143–6153. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Markaverich BM, Shoulars K and Rodriguez
MA: Luteolin regulation of estrogen signaling and cell cycle
pathway genes in MCF-7 human breast cancer cells. Int J Biomed Sci.
7:101–111. 2011.PubMed/NCBI
|
|
52
|
Dantzer F, Schreiber V, Niedergang C,
Trucco C, Flatter E, De La Rubia G, Oliver J, Rolli V, Ménissier-de
Murcia J and de Murcia G: Involvement of poly(ADP-ribose)
polymerase in base excision repair. Biochimie. 81:69–75. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Song D, Huang H, Wang J, Zhao Y, Hu X, He
F, Yu L and Wu J: NF90 regulates PARP1 mRNA stability in
hepatocellular carcinoma. Biochem Biophys Res Commun. 488:211–217.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ko HL and Ren EC: Novel poly (ADP-ribose)
polymerase 1 binding motif in hepatitis B virus core promoter
impairs DNA damage repair. Hepatology. 54:1190–1198. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Mukherjee RM, Shravanti GV, Jakkampudi A,
Kota R, Jangala AL, Reddy PB, Rao PN, Gupta R and Reddy DN: Reduced
expression of DNA damage repair genes high mobility group box1 and
Poly(ADP-ribose) polymerase1 in inactive carriers of hepatitis B
virus infection-A possible stage of viral integration. J Clin Exp
Hepatol. 3:89–95. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Qadri I, Fatima K and AbdeL-Hafiz H:
Hepatitis B virus X protein impedes the DNA repair via its
association with transcription factor, TFIIH. BMC Microbiol.
11:482011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hashimoto S and Egly JM:
Trichothiodystrophy view from the molecular basis of DNA
repair/transcription factor TFIIH. Hum Mol Genet. 18:R224–R230.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Schärer OD: Hot topics in DNA repair: The
molecular basis for different disease states caused by mutations in
TFIIH and XPG. DNA Repair (Amst). 7:339–344. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Lee TH, Elledge SJ and Butel JS: Hepatitis
B virus X protein interacts with a probable cellular DNA repair
protein. J Virol. 69:1107–1114. 1995.PubMed/NCBI
|
|
60
|
Djouder N: Boosting NAD(+) for the
prevention and treatment of liver cancer. Mol Cell Oncol.
2:e10011992015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Boniol M and Autier P: Prevalence of main
cancer lifestyle risk factors in Europe in 2000. Eur J Cancer.
46:2534–2544. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Grohmann M, Wiede F, Dodd GT, Gurzov EN,
Ooi GJ, Butt T, Rasmiena AA, Kaur S, Gulati T, Goh PK, et al:
Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC.
Cell. 175:1289–1306 e20. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Park EJ, Lee JH, Yu GY, He G, Ali SR,
Holzer RG, Osterreicher CH, Takahashi H and Karin M: Dietary and
genetic obesity promote liver inflammation and tumorigenesis by
enhancing IL-6 and TNF expression. Cell. 140:197–208. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Xiong Y, Zhang J, Liu M, An M, Lei L and
Guo W: Human leptin protein activates the growth of HepG2 cells by
inhibiting PERK-mediated ER stress and apoptosis. Mol Med Rep.
10:1649–1655. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Vansaun MN, Mendonsa AM and Lee Gorden D:
Hepatocellular proliferation correlates with inflammatory cell and
cytokine changes in a murine model of nonalchoholic fatty liver
disease. PLoS One. 8:e730542013. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Li S, Mo C, Huang S, Yang S, Lu Y, Peng Q,
Wang J, Deng Y, Qin X and Liu Y: Over-expressed Testis-specific
Protein Y-encoded 1 as a novel biomarker for male hepatocellular
carcinoma. PLoS One. 9:e892192014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Montella M, D'Arena G, Crispo A, Capunzo
M, Nocerino F, Grimaldi M, Barbieri A, D'Ursi AM, Tecce MF, Amore
A, et al: Role of sex hormones in the development and progression
of hepatitis B virus-associated hepatocellular carcinoma. Int J
Endocrinol. 2015:8545302015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Beato M and Klug J: Steroid hormone
receptors: An update. Hum Reprod Update. 6:225–236. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Chang CS, Kokontis J and Liao ST:
Molecular cloning of human and rat complementary DNA encoding
androgen receptors. Science. 240:324–326. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Wu MH, Ma WL, Hsu CL, Chen YL, Ou JH, Ryan
CK, Hung YC, Yeh S and Chang C: Androgen receptor promotes
hepatitis B virus-induced hepatocarcinogenesis through modulation
of hepatitis B virus RNA transcription. Sci Transl Med.
2:32ra352010. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Barone M, Margiotta M, Scavo MP, Gentile
A, Francioso D, Papagni S, Castellaneta A, Mallamaci R, Di Leo A
and Francavilla A: Possible involvement of androgen receptor
alterations in hepatocarcinogenesis. Dig Liver Dis. 41:665–670.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Ma WL, Hsu CL, Wu MH, Wu CT, Wu CC, Lai
JJ, Jou YS, Chen CW, Yeh S and Chang C: Androgen receptor is a new
potential therapeutic target for the treatment of hepatocellular
carcinoma. Gastroenterology. 135:947–955, 955.e1-5. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Yang WJ, Chang CJ, Yeh SH, Lin WH, Wang
SH, Tsai TF, Chen DS and Chen PJ: Hepatitis B virus X protein
enhances the transcriptional activity of the androgen receptor
through c-Src and glycogen synthase kinase-3beta kinase pathways.
Hepatology. 49:1515–1524. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Feng H, Cheng AS, Tsang DP, Li MS, Go MY,
Cheung YS, Zhao GJ, Ng SS, Lin MC, Yu J, et al: Cell cycle-related
kinase is a direct androgen receptor-regulated gene that drives
β-catenin/T cell factor-dependent hepatocarcinogenesis. J Clin
Invest. 121:3159–3175. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Koh WP, Yuan JM, Wang R, Govindarajan S,
Oppenheimer R, Zhang ZQ, Yu MC and Ingles SA: Aromatase (CYP19)
promoter gene polymorphism and risk of nonviral hepatitis-related
hepatocellular carcinoma. Cancer. 117:3383–3392. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Castagnetta LA, Agostara B, Montalto G,
Polito L, Campisi I, Saetta A, Itoh T, Yu B, Chen S and Carruba G:
Local estrogen formation by nontumoral, cirrhotic, and malignant
human liver tissues and cells. Cancer Res. 63:5041–5045.
2003.PubMed/NCBI
|
|
77
|
Zhang S, Shu R, Yue M and Zhang S: Effect
of over-expression of zinc-finger protein (ZFX) on self-renewal and
drug-resistance of hepatocellular carcinoma. Med Sci Monit.
22:3025–3034. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Park SJ, Jeong SY and Kim HJ: Y chromosome
loss and other genomic alterations in hepatocellular carcinoma cell
lines analyzed by CGH and CGH array. Cancer Genet Cytogenet.
166:56–64. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Liu J, Wang ZM, Zhen SF, Wu XP, Ma DX, Li
ZH, Liu B, Zhao ZL and Ke Y: Aberration of X chromosome in liver
neoplasm detected by fluorescence in situ hybridization.
Hepatobiliary Pancreat Dis Int. 3:110–114. 2004.PubMed/NCBI
|
|
80
|
Lalli E and Alonso J: Targeting DAX-1 in
embryonic stem cells and cancer. Expert Opin Ther Targets.
14:169–177. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Li H, Zhang Z, Bi Y, Yang D, Zhang L and
Liu J: Expression characteristics of β-catenin in scallop Chlamys
farreri gonads and its role as a potential upstream gene of Dax1
through canonical Wnt signalling pathway regulating the
spermatogenesis. PLoS One. 9:e1159172014. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Campbell DEK and Langlois VS: Expression
of sf1 and dax-1 are regulated by thyroid hormones and androgens
during Silurana tropicalis early development. Gen Comp Endocrinol.
259:34–44. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Tsuei DJ, Lee PH, Peng HY, Lu HL, Su DS,
Jeng YM, Hsu HC, Hsu SH, Wu JF, Ni YH and Chang MH: Male germ
cell-specific RNA binding protein RBMY: A new oncogene explaining
male predominance in liver cancer. PLoS One. 6:e269482011.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Yin YH, Li YY, Qiao H, Wang HC, Yang XA,
Zhang HG, Pang XW, Zhang Y and Chen WF: TSPY is a cancer testis
antigen expressed in human hepatocellular carcinoma. Br J Cancer.
93:458–463. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Murakami S, Chishima S, Uemoto H, Sakamoto
E, Sato T, Kurabe N, Kawasaki Y, Shibata T, Akiyama H and Tashiro
F: The male-specific factor Sry harbors an oncogenic function.
Oncogene. 33:2978–2986. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Murakami S, Ninomiya W, Sakamoto E,
Shibata T, Akiyama H and Tashiro F: SRY and OCT4 are required for
the acquisition of cancer stem cell-like properties and are
potential differentiation therapy targets. Stem Cells.
33:2652–2663. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Tsuei DJ, Hsu HC, Lee PH, Jeng YM, Pu YS,
Chen CN, Lee YC, Chou WC, Chang CJ, Ni YH and Chang MH: RBMY, a
male germ cell-specific RNA-binding protein, activated in human
liver cancers and transforms rodent fibroblasts. Oncogene.
23:5815–5822. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Homayounfar K, Schwarz A, Enders C,
Cameron S, Baumhoer D, Ramadori G, Lorf T, Gunawan B and Sander B:
Etiologic influence on chromosomal aberrations in European
hepatocellular carcinoma identified by CGH. Pathol Res Pract.
209:380–387. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Hashimoto K, Mori N, Tamesa T, Okada T,
Kawauchi S, Oga A, Furuya T, Tangoku A, Oka M and Sasaki K:
Analysis of DNA copy number aberrations in hepatitis C
virus-associated hepatocellular carcinomas by conventional CGH and
array CGH. Mod Pathol. 17:617–622. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Takeo S, Arai H, Kusano N, Harada T,
Furuya T, Kawauchi S, Oga A, Hirano T, Yoshida T, Okita K and
Sasaki K: Examination of oncogene amplification by genomic DNA
microarray in hepatocellular carcinomas: Comparison with
comparative genomic hybridization analysis. Cancer Genet Cytogenet.
130:127–132. 2001. View Article : Google Scholar : PubMed/NCBI
|
